Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.

Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. Clin Cancer Res. 2002 Sep; 8(9):2812-9.

View in: PubMed

subject areas

Acute Disease
Age Factors
Aged
Antineoplastic Combined Chemotherapy Protocols
Combined Modality Therapy
Cyclosporins
Cytarabine
Daunorubicin
Disease-Free Survival
Drug Administration Schedule
Etoposide
Fatigue
Gene Expression Regulation, Neoplastic
Hematologic Diseases
Humans
Immunologic Factors
Interleukin-2
Killer Cells, Natural
Leukemia, Myeloid
Life Tables
Middle Aged
Nausea
Neoplasm Proteins
NK Cell Lectin-Like Receptor Subfamily K
Receptors, Immunologic
Receptors, Natural Killer Cell
Recombinant Fusion Proteins
Remission Induction
Survival Analysis
Treatment Outcome

authors with profiles

Richard A. Larson